| Literature DB >> 24184352 |
Ina Huppertz1, Jan Attig1, Andrea D'Ambrogio1, Laura E Easton2, Christopher R Sibley1, Yoichiro Sugimoto2, Mojca Tajnik3, Julian König4, Jernej Ule5.
Abstract
RNA-binding proteins (RBPs) are key players in the post-transcriptional regulation of gene expression. Precise knowledge about their binding sites is therefore critical to unravel their molecular function and to understand their role in development and disease. Individual-nucleotide resolution UV crosslinking and immunoprecipitation (iCLIP) identifies protein-RNA crosslink sites on a genome-wide scale. The high resolution and specificity of this method are achieved by an intramolecular cDNA circularization step that enables analysis of cDNAs that truncated at the protein-RNA crosslink sites. Here, we describe the improved iCLIP protocol and discuss critical optimization and control experiments that are required when applying the method to new RBPs.Entities:
Keywords: High-throughput sequencing; Post-transcriptional regulation; Protein–RNA interaction; RNA; RNA-binding protein; UV crosslinking and immunoprecipitation (CLIP); iCLIP
Mesh:
Substances:
Year: 2013 PMID: 24184352 PMCID: PMC3988997 DOI: 10.1016/j.ymeth.2013.10.011
Source DB: PubMed Journal: Methods ISSN: 1046-2023 Impact factor: 3.608
Fig. 1Schematic representation of the iCLIP procedure identifying RNA–protein interactions in intact cells. Cells are irradiated with UV-C light on ice, leading to formation of a covalent bond between protein and RNA. This is followed by partial RNase digestion and an immunoprecipitation with protein-specific antibodies. For the library preparation and visualization, the RNA is dephosphorylated, a 3′ end adapter is ligated and the 5′ end is radioactively labeled. The complexes are separated by SDS–PAGE and isolated from a nitrocellulose membrane according to the expected size. The protein is then digested by proteinase K, and reverse transcription (RT) is performed truncating at the remaining polypeptide. The RT primer introduces two cleavable adapter regions and barcode sequences. The free RT primers are removed by size selection and circularization of the cDNA is carried out. Linearization generates suitable templates for PCR amplification. In the last step, high-throughput sequencing generates reads in which the barcode sequences are immediately followed by the last nucleotide of the cDNA.
Improvements compared to the previous protocol, which was published in the Journal of Visualized Experiments [19].
| Original protocol | Improved protocol | Reason for the change | Benefit of the change |
|---|---|---|---|
| 25 and 40 mM dithiothreitol in the 5x PNK pH 6.5 and the 4x ligation buffer, respectively | 5 and 4 mM dithiothreitol in the 5x PNK pH 6.5 and the 4x ligation buffer, respectively | High concentration of DTT can decrease the immunoprecipitation efficiency | Increased recovery of protein–RNA complexes, as visualized on the radiograph |
| No 4-thiouridine pre-incubation | Optional 4-thiouridine pre-incubation and UV-A crosslinking | Special modifications are required for certain proteins | 4-thiouridine enhances crosslinking of certain proteins |
| Optional sonication | Use of bioruptor enables uniform sonication of multiple samples | Sonication shears the DNA, which releases proteins from the chromatin | Increased recovery of protein–RNA complexes, as visualized on the radiograph ( |
| Use phenol/chloroform pH 4.5 | Use phenol/chloroform pH 6.7 | L3 is a DNA adapter ligated to the RNA creating an DNA–RNA hybrid | Reduction of DNA-RNA hybrids in phenol phase |
| Radioactive RNA carried over into PCR | Alkaline hydrolysis degrades RNA after reverse transcription | The carryover RNA is radioactive and might inhibit cDNA circularization | Reduction of radioactive signal after reverse transcription ( |
| No phenol/chloroform extraction after cDNA recovery | Additional phenol/ chloroform extraction after cDNA recovery from TBE-urea gel | Carryover of urea and polyacrylamide after gel extraction can decrease CircLigase II efficiency | Increased efficiency of cDNA circularization due to removal of potential contaminants |
| Preparative PCR in the same volume as the PCR optimization | Increased the volume of the preparative PCR | High cDNA concentration in the preparative PCR can introduce salts that may inhibit PCR amplification | Consistent efficiency of PCR amplification |
| No stringent urea treatment | Optional stringent purification strategy with urea | Special modifications are required for certain proteins | Removal of co-purification of RBPs that strongly interact with the protein of interest ( |
Fig. 2Tests using photo-reactive nucleosides and sonication. (A) Increasing concentrations of 4-thiouridine (4SU) or 6-thioguanosine (6GU) lead to cell death in HeLa cells. HeLa cells were treated with 4SU (4SU; 25 μM, 100 μM and 500 μM) or 6SG (6SG; 25 μM, 100 μM) over a time course of 96 h. Viable cells were counted using trypan blue staining at different time points, and normalized to the initial cell numbers (depicted as log2). Dead cells were counted at each time point using trypan blue and displayed as percentage of total cell numbers at this time point. (B) Increasing concentrations of 4SU or 6SG inhibit growth of HEK293 cells. HEK293 cells were treated with 4SU (25 μM, 100 μM and 500 μM) or 6SG (5 μM, 25 μM, 100 μM) over a time course of 96 or 48 h, respectively. Display as in (A). (C) hnRNP C can be crosslinked with either UV-C or UV-A light in combination with 4SU. Autoradiograph showing radioactively labeled hnRNP C protein–RNA complexes. 4SU incubation for 30 and 60 min was followed by crosslinking by UV-A light and compared to UV-C crosslinking. Samples without antibody serve as controls. The size of uncrosslinked hnRNP C protein is labeled on the right. (D) Autoradiograph of radioactively labeled protein–RNA complexes immunoprecipitated with antibodies against endogenous TIA1 or hnRNP C. Since sonication can free chromatin-associated proteins, samples were either sonicated or left untreated before immunoprecipitation, and RNA was digested with a 1/50 dilution of RNase I. Samples without antibody serve as controls. Sizes of uncrosslinked proteins are labeled on the right. The asterisk indicates the hnRNP C dimer.
Fig. 3Tests for dephosphorylation and partial RNase digestion. (A) Optimization of RNase I concentration is crucial to obtain optimal fragment sizes. Autoradiograph showing hnRNP C protein–RNA complexes that were treated with decreasing concentrations of RNase I before immunoprecipitation. Markings on the right (A–E) indicate five size ranges that were cut from the nitrocellulose membrane. A sample without antibody serves as control. The sizes of uncrosslinked hnRNP C and hnRNP C dimers are marked by an arrowhead and an asterisk, respectively. (B) Partial RNase digestion with a 1/250 dilution yields an optimal distribution of recovered RNA fragment sizes. Size separation of RNA fractions isolated from hnRNP C protein–RNA complexes through proteinase K digestion. RNA was isolated from five regions of the nitrocellulose membrane (A–E, see labeling in (A)) for three differently treated samples (1/50, 1/250 and 1/500 dilutions of RNase I). (C) PNK treatment for 20 min is the most efficient for 3′ end dephosphorylation. PTB protein–RNA complexes were treated either with Shrimp Alkaline Phosphatase (SAP) for 20 min or with Polynucleotide Kinase (PNK) for 20 min or 2 h, and the cDNA yield was compared after library preparation. A sample without antibody serves as control.
Fig. 4Quality improvements of library preparation and urea treatment. (A) Reverse transcription (RT) primers can differ in their efficiency. Different reverse transcription primers were tested by analyzing hnRNP C iCLIP libraries using gel electrophoresis. RT primers Rt#clip 1, 2, 6, 9, 10 and 13–16 were identified as the most useful for library preparation. Note that in this experiment also the control omitting the antibody shows product on the PCR gel, indicating some impurities in the purification. For the evaluation of the primer quality this does not have an impact. Furthermore, the signal of the product is much weaker when compared to the sample that was reverse transcribed with the same RT primer (Rt9clip). (B) Alkaline hydrolysis efficiently removes radioactively labeled RNA and does not impair library preparation. Gel image of amplified cDNA libraries using RT primers Rt1clip and Rt2clip and extraction of low and medium size ranges (L, 70–80 nt; M, 80–100 nt). Samples were treated with or without alkaline hydrolysis. Radioactive counts per second before RT and after gel extraction are given above. (C) Increased numbers of PCR amplification cycles lead to the formation of secondary products. hnRNP C iCLIP libraries were amplified using between 21 and 39 cycles. The appearance of secondary products beyond 31 cycles indicates overamplification. 1/10 and 1/100 dilutions of cycle number 35 and 39 are shown for comparison.
Fig. 5Alternative IP using urea treatment. Denaturing urea treatment prevents co-purification of a second RBP of about 40 kDa. FLAG-tagged Staufen 1 (STAU1) was purified using the standard iCLIP protocol (no urea treatment) and compared to an immunoprecipitation procedure using denaturing urea treatment.
| Buffer | Ingredients |
|---|---|
| Lysis buffer | 50 mM Tris–HCl, pH 7.4 |
| 100 mM NaCl | |
| 1% Igepal CA-630 | |
| 0.1% SDS | |
| 0.5% sodium deoxycholate | |
| On the day: 1/100 volume of Protease Inhibitor Cocktail Set III, for tissues: 1/1000 volume of ANTI-RNase | |
| High-salt Wash | 50 mM Tris–HCl, pH 7.4 |
| 1 M NaCl | |
| 1 mM EDTA | |
| 1% Igepal CA-630 | |
| 0.1% SDS | |
| 0.5% sodium deoxycholate | |
| PNK buffer | 20 mM Tris–HCl, pH 7.4 |
| 10 mM MgCl2 | |
| 0.2% Tween-20 | |
| 5x PNK pH 6.5 buffer | 350 mM Tris–HCl, pH 6.5 |
| 50 mM MgCl2 | |
| 5 mM dithiothreitol | |
| Freeze aliquots of the buffer, do not thaw and freeze again | |
| 4x Ligation buffer | 200 mM Tris–HCl, pH 7.8 |
| 40 mM MgCl2 | |
| 4 mM dithiothreitol | |
| Freeze aliquots of the buffer, do not thaw and freeze again | |
| PK buffer | 100 mM Tris–HCl, pH 7.4 |
| 50 mM NaCl | |
| 10 mM EDTA | |
| PK buffer + 7 M urea | 100 mM Tris–HCl, pH 7.4 |
| 50 mM NaCl | |
| 10 mM EDTA | |
| 7 M urea |
| Material | Manufacturer |
|---|---|
| Stratalinker UV crosslinker 2400 | Stratagene |
| 4-Thiouridine | Sigma (T4509) |
| Protein G Dynabeads | Life Technologies (10004D) |
| Protein A Dynabeads | Life Technologies (10002D) |
| Protease Inhibitor Cocktail Set III | Calbiochem/Merck (539134-1SET) |
| ANTI-RNase | Life Technologies (AM2692) |
| RNase I | Life Technologies (AM2295) |
| Turbo DNase | Life Technologies (AM2238) |
| T4 PNK plus 10x PNK buffer | NEB (M0201L) |
| RNasin | Promega (N2515) |
| Proteus Clarification Mini Spin Columns | Generon (GEN-MSF500) |
| T4 RNA Ligase I | NEB (M0204L) |
| Pre-adenylated adapter L3-App | IDT (rAppAGATCGGAAGAGCGGTTCAG/ddC/) |
| ATP [γ-32P] | Perkin Elmer (NEG502A250UC) |
| Material | Manufacturer |
|---|---|
| 4–12% NuPAGE gels | Life Technologies (NP0322BOX) |
| Electrophoresis chamber | Life Technologies (EI0002) |
| Transfer apparatus | Life Technologies (EI0002) |
| LDS-4x sample buffer | Life Technologies (NP0007) |
| Pre-stained protein marker | Fermentas (SM1811) |
| Nitrocellulose membrane protran BA85 | VWR (732-4174) |
| Sponge pads for XCell II blotting | Life Technologies (EI9052) |
| 20 × transfer buffer | Life Technologies (NP0006-1) |
| 20 × MOPS-SDS running buffer | Life Technologies (NP0001) |
| Whatman filter paper | GE Healthcare (3030917) |
| Film | Fuji (4741019236) |
| Material | Manufacturer |
|---|---|
| Proteinase K | Fisher Scientific (YSJ-762-Q) |
| 19G syringe needles | BD Microlance (304000) |
| Phenol/chloroform | Sigma (P3803) |
| Phase lock gel heavy tube | VWR (713-2536) |
| Glycoblue | Ambion (9510) |
| 3 M sodium acetate pH 5.5 | Life Technologies (AM9740) |
| Material | Manufacturer |
|---|---|
| PCR tubes | VWR (732-0545) |
| dNTPs | Promega (1009310) |
| Superscript III | Life Technologies (18080085) |
| 5X First-strand buffer | Life Technologies (18080085) |
| DTT | Life Technologies (18080085) |
| 1 M HEPES pH 7.3 | Thermo Scientific (BP299-500) |
| TE buffer | VWR (A2575) |
| Name | Sequence (IDT) |
|---|---|
| Rt1clip | /5Phos/NNAACCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt2clip | /5Phos/NNACAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt3clip | /5Phos/NNATTGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt4clip | /5Phos/NNAGGTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt6clip | /5Phos/NNCCGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt7clip | /5Phos/NNCTAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt8clip | /5Phos/NNCATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt9clip | /5Phos/NNGCCANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt11clip | /5Phos/NNGGTTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt12clip | /5Phos/NNGTGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt13clip | /5Phos/NNTCCGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt14clip | /5Phos/NNTGCCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt15clip | /5Phos/NNTATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Rt16clip | /5Phos/NNTTAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC |
| Material | Manufacturer |
|---|---|
| 2x TBE – urea loading buffer | Life Technologies (LC6876) |
| 6% TBE – urea pre-cast gels | Life Technologies (EC68652B) |
| Low molecular weight marker | NEB (N3233L) |
| TBE running buffer | Life Technologies (LC6675) |
| SYBR green II | Life Technologies (S-7564) |
| 19G syringe needle | BD Microlance (300637) |
| Glass pre-filters | Whatman (1823010) |
| Phase lock gel heavy | VWR (713-2536) |
| Costar SpinX column | Corning Incorporated (8161) |
| Material | Manufacturer |
|---|---|
| 10x CircLigase buffer | Cambio (CL9025K) |
| CircLigase II | Cambio (CL9025K) |
| MnCl2 | Cambio (CL9025K) |
| Cut_oligo | GTTCAGGATCCACGACGCTCTTCaaaa |
| BamHI | Fermentas, FD0055 |
| Fast digest buffer | Fermentas, FD0055 |
| Material | Manufacturer |
|---|---|
| Accuprime Supermix I | Life Technologies (12342028) |
| SYBR green I | Life Technologies (S-7563) |
| P5 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT |
| P3 | CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT |
| Material | Manufacturer |
|---|---|
| Accuprime Supermix I | Life Technologies (12342028) |
| PhiX control library (RNAseq/ChIPseq) | Illumina (PC-110-3001) |
| Platinium Taq mastermix | Life Technologies (11743100) |
| DLP | [6FAM] CCCTACACGACGCTCTTCCGATCT [TAMRA] |
| Primer 1 | AATGATACGGCGACCACCGAGATC |
| Primer 2 | CAAGCAGAAGACGGCATACGAGATC |
| Buffer | Ingredients |
|---|---|
| Urea cracking buffer | 50 mM Tris–HCl, pH 7.4 |
| 6 M urea | |
| 1% SDS | |
| 25% PBS | |
| T-20 IP buffer | 50 mM Tris–HCl, pH 7.4 |
| 150 mM NaCl | |
| 0.5% Tween 20 | |
| 0.1 mM EDTA |
| Material | Manufacturer |
|---|---|
| Dynabeads Antibody Coupling Kit | Life Technologies (14311D) |
| SUPERase• in™ RNase inhibitor | Life Technologies (AM2694) |
| NuPAGE sample reducing agent | Life Technologies (NP0004) |
| NuPAGE antioxidant | Life Technologies (NP0005) |
| Linear acrylamide | Life Technologies (AM9520) |
| 4 μl | 5 × PNK pH 6.5 buffer |
| 0.5 μl | PNK |
| 0.5 μl | RNasin |
| 15 μl | H2O |
| 8 μl | H2O |
| 5 μl | 4X ligation buffer |
| 1 μl | RNA ligase |
| 0.5 μl | RNasin |
| 1.5 μl | pre-adenylated adapter L3-App (20 μM) |
| 4 μl | PEG400 |
| 0.2 μl | PNK |
| 0.4 μl | γ-32P-ATP |
| 0.4 μl | 10x PNK buffer |
| 3 μl | H2O |
| 1 μl primer Rt#clip (0.5 pmol/μl) |
| 1 μl dNTP mix (10 mM) |
| 7 μl | H2O |
| 4 μl | 5 × First Strand Buffer |
| 1 μl | 0.1 M DTT |
| 0.5 μl | RNasin |
| 0.5 μl | Superscript III |
| 6.5 μl H2O |
| 0.8 μl 10x CircLigase buffer II |
| 0.4 μl 50 mM MnCl2 |
| 0.3 μl CircLigase II |
| 26 μl | H2O |
| 3 μl | Fast digest buffer |
| 1 μl | 10 μM Cut_oligo |
| 95 °C 2 min. |
| Successive cycles of 20 s, starting from 95 °C and decreasing the temperature by 1 °C each cycle down to 25 °C. |
| 25 °C hold. |
| 1 μl cDNA |
| 0.25 μl primer mix P5Solexa/P3Solexa, 10 μM each |
| 5 μl Accuprime Supermix 1 |
| 3.75 μl H2O |
| 94 °C 2 min |
| 25–35 cycles of: 94 °C 15 s, 65 °C 30 s, 68 °C 30 s |
| 68 °C 3 min |
| 25 °C hold |
| 10 μl | cDNA |
| 9 μl | H2O |
| 1 μl | primer mix P5Solexa/P3Solexa, 10 μM each |
| 20 μl | Accuprime Supermix 1 |
| 10 μl | Invitrogen Platinum qPCR Supermix w/ROX |
| 0.5 μl | DLP oligo (10 μM) |
| 0.6 μl | primer 1 (10 μM) |
| 0.6 μl | primer 2 (10 μM) |
| 6.3 μl | H2O |